Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Keros Therapeutics Inc (NQ: KROS )

63.07 -1.81 (-2.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Keros Therapeutics Inc

< Previous 1 2 Next >
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Where Keros Therapeutics Stands With Analysts
Via Benzinga
Recap: Keros Therapeutics Q1 Earnings
Via Benzinga
Recap: Keros Therapeutics Q3 Earnings
Keros Therapeutics (NASDAQ:KROS) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024
KROS stock results show that Keros Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
Via Benzinga
Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial
Via Benzinga
Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure
Via Benzinga
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
Via Benzinga
Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 144.5% to $0.7827. 
Via Benzinga
Why Shares of Keros Therapeutics Jumped This Week
The company appointed a new director and an analyst reiterated his position on the stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
Via Benzinga
Why Shares of Keros Therapeutics Rose 10.2% This Week
A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher. 
Via The Motley Fool
Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Monday. Here are some big stocks recording gained in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 216 stocks hit new 52-week lows. 
Via Benzinga
76 Biggest Movers From Yesterday
Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.